日盈電子(603286.SH):目前公司無人形機器人相關業務收入
格隆匯8月4日丨日盈電子(603286.SH)公佈股票交易異常波動公吿,公司關注到有媒體報道將公司列為人形機器人的相關概念股,經公司自查,公司在2024年年度報吿中提到公司在佈局電子皮膚產品,特針對該產品進一步説明如下:公司應用於人形機器人領域的電子皮膚產品是基於自身原來在汽車領域温度傳感器、壓力傳感器等傳感器的技術延伸開發的產品,目前公司電子皮膚產品無客户,無訂單,無相關業務收入,未來是否能夠如期完成產品匹配及未來需求量存在不確定性,目前公司電子皮膚產品對公司業績不形成影響。目前公司無人形機器人相關業務收入。因此,公司特別提醒廣大投資者理性決策,審慎投資,注意相關風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.